post-hoc analysis of sequential afatinib and osimertinib in nsclc patients
Published 2 years ago • 1K plays • Length 9:27Download video MP4
Download video MP3
Similar videos
-
8:47
study of 693 nsclc patients treated with afatinib
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
11:53
insight 2: a phase ii study of tepotinib plus osimertinib in met-amplified nsclc
-
6:43
sequential afatinib and osimertinib in egfr mutation-positive nsclc patients: updated results
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
35:08
cancer survivor story: my successful targeted therapy treatment | ashley's story (2 of 3)
-
19:07
interpreting pulmonary function tests #anesthesiatools #bbb | saneesh
-
30:32
2023 best of lung: targeted therapies in lung cancer
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
2:34
giotag: real world data on first-line afatinib followed by osimertinb
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
5:24
case 4: egfr mutation analysis post-osimertinib
-
1:42
adaura: the benefit of adjuvant osimertinib
-
6:52
afatinib vs erlotinib in chinese patients with advanced sccof the lung- video abstract id 161506
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
3:38
overview of the world of egfr mutant lung cancers
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
0:58
the activity of afatinib in lung cancer
-
1:31
dr. gold on the future of osimertinib in lung cancer